The American Journal of Medicine
Volume 122, Issue 9 , Pages 843-850 , September 2009

Psychiatric Comorbidity and Other Psychological Factors in Patients with “Chronic Lyme Disease”

  • Afton L. Hassett, PsyD

      Affiliations

    • Division of Rheumatology and Connective Tissue Research, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, New Brunswick, NJ
    • Department of Medicine, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, New Brunswick, NJ
    • Corresponding Author InformationRequests for reprints should be addressed to Afton L. Hassett, PsyD, UMDNJ-Robert Wood Johnson Medical School, 1 R W Johnson Place MEB-484, New Brunswick, NJ 08903-0019
    • ,
  • Diane C. Radvanski, MS

      Affiliations

    • Division of Rheumatology and Connective Tissue Research, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, New Brunswick, NJ
    • ,
  • Steven Buyske, PhD

      Affiliations

    • Department of Statistics, Rutgers University, Piscataway, NJ
    • ,
  • Shantal V. Savage, BA

      Affiliations

    • Division of Rheumatology and Connective Tissue Research, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, New Brunswick, NJ
    • ,
  • Leonard H. Sigal, MD

      Affiliations

    • Division of Rheumatology and Connective Tissue Research, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, New Brunswick, NJ
    • Department of Medicine, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, New Brunswick, NJ
    • Lyme Disease Center, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, New Brunswick, NJ
    • Department of Molecular Genetics & Microbiology, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, New Brunswick, NJ
    • Pharmaceutical Research Institute, Bristol-Myers Squibb, Princeton, NJ

References 

  1. Steere AC. Lyme disease. N Engl J Med. 2001;345:115–124
  2. Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2006;43:1089–1134
  3. Asch ES, Bujak DI, Weiss M, et al. Lyme disease: an infectious and postinfectious syndrome. J Rheumatol. 1994;21:454–461
  4. Bujak DI, Weinstein A, Dornbush RL. Clinical and neurocognitive features of the post Lyme syndrome. J Rheumatol. 1996;23:1392–1397
  5. Seltzer EG, Gerber MA, Cartter ML, et al. Long-term outcomes of persons with Lyme disease. JAMA. 2000;283(5):609–616
  6. Shadick NA, Phillips CB, Logigian EL, et al. The long-term clinical outcomes of Lyme disease (A population-based retrospective cohort study). Ann Intern Med. 1994;121(8):560–567
  7. Shadick NA, Phillips CB, Sangha O, et al. Musculoskeletal and neurologic outcomes in patients with previously treated Lyme disease. Ann Intern Med. 1999;131:919–926
  8. Smith RP, Schoen RT, Rahn DW, et al. Clinical characteristics and treatment outcome of early Lyme disease in patients with microbiologically confirmed erythema migrans. Ann Intern Med. 2002;136:421–428
  9. Yrjänäinen H, Hytönen J, Song XY, et al. Anti-tumor necrosis factor-alpha treatment activates Borrelia burgdorferi spirochetes 4 weeks after ceftriaxone treatment in C3H/He mice. J Infect Dis. 2007;195:1489–1496
  10. Klempner MS. Controlled trials of antibiotic treatment in patients with post-treatment chronic Lyme disease. Vector Borne Zoonotic Dis. 2002;2:255–263
  11. Marques AR, Stock F, Gill V. Evaluation of a new culture medium for Borrelia burgdorferi. J Vet Diagnos Invest. 2000;3:350–352
  12. Feder HM, Johnson BJ, O'Connell S, et al. A critical appraisal of “chronic Lyme disease”. N Engl J Med. 2007;357:1422–1430
  13. Cameron D, Gaito A, Harris N, et al. ILADS Working Group Evidence-based guidelines for the management of Lyme disease. Expert Rev Anti Infect Ther. 2004;2(1 Suppl):S1–S13
  14. Sigal LH. Summary of the first 100 patients seen at a Lyme disease referral center. Am J Med. 1990;88:577–581
  15. Sigal LH. The Lyme disease controversy (Social and financial costs of misdiagnosis and mismanagement). Arch Intern Med. 1996;156:1493–1500
  16. Sigal LH, Hassett AL. Commentary: ‘What’s in a name? That which we call a rose by any other name would smell as sweet.' (Shakespeare W. Romeo and Juliet, II, ii(47-48)). Int J Epidemiol. 2005;34:1345–1347
  17. Klempner MS, Hu LT, Evans J, et al. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N Engl J Med. 2001;345:85–92
  18. Hsu VM, Patella SJ, Sigal LH. Chronic Lyme disease as the incorrect diagnosis in patients with fibromyalgia. Arthritis Rheum. 1993;36:1493–1500
  19. Reid MC, Schoen RT, Evans J, et al. The consequences of overdiagnosis and overtreatment of Lyme disease: an observational study. Ann Intern Med. 1998;128:354–362
  20. Steere AC, Taylor E, McHugh GL, Logigian EL. The overdiagnosis of Lyme disease. JAMA. 1993;269:1812–1816
  21. Klempner MS, Schmid CH, Hu L, et al. Intralaboratory reliability of serologic and urine testing for Lyme disease. Am J Med. 2001;110:217–219
  22. Fukuda K, Nisenbaum R, Stewart G, et al. Chronic multisymptom illness affecting Air Force veterans of the Gulf War. JAMA. 1998;280:981–988
  23. Sigal LH, Hassett AL. Contributions of societal and geographical environments to “Chronic Lyme Disease”: the psychopathogenesis and aporology of a new “medically unexplained symptoms” syndrome. Environ Health Perspect. 2002;110(Suppl 4):607–611
  24. Solomon SP, Hilton E, Weinschel BS, et al. Psychological factors in the prediction of Lyme disease course. Arthritis Care Res. 1998;11:419–426
  25. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR), 4th edn, text revision. Washington, DC: American Psychiatric Press, Inc; 2000;
  26. Wharton M, Chorba TL, Vogt RL, et al. Case definitions for public health surveillance. MMWR Recomm Rep. 1990;39(RR-13):1–43
  27. Wormser GP, Nadelman RB, Dattwyler RJ, et al. Guidelines from the Infectious Disease Society of America (Practice guidelines for the treatment of Lyme disease). Clin Infect Dis. 2000;31(Suppl 1):S1–S14
  28. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the multicenter criteria committee. Arthritis Rheum. 1990;33:160–172
  29. Spitzer RL, Williams JB, Kroenke K, et al. Utility of a new procedure for diagnosing mental disorders in primary care (The PRIME-MD 1000 study). JAMA. 1994;272:1749–1756
  30. Spitzer RL, Williams JB, Gibbon M, First MB. The Structured Clinical Interview for DSM-III-R (SCID) (I: History, rationale, and description). Arch Gen Psychiatry. 1992;49(8):624–629
  31. Millon T, Davis R, Millon C. MCMI-III Manual. 2nd edn.. Minneapolis: NCS Pearson, Inc; 1997;
  32. Rogers R, Salekin RT, Sewell KW. Validation of the Millon Clinical Multiaxial Inventory for disorders: does it meet the Daubert standard?. Law Hum Behav. 1999;23:425–443
  33. Guthrie PC, Mobley BD. A comparison of the differential diagnostic efficiency of three personality disorder inventories. J Clin Psychol. 1994;50:656–665
  34. Rosenstiel AK, Keefe FJ. The use of coping strategies in lower back pain patients: relationships to patient characteristics and current adjustment. Pain. 1983;17:33–40
  35. Edwards RR, Bingham CO, Bathon J, Haythornthwaite JA. Catastrophizing and pain in arthritis, fibromyalgia, and other rheumatic diseases. Arthritis Rheum. 2006;55:325–332
  36. Swartzman LC, Gwadry FG, Shapiro AP, Teasell RW. The factor structure of the Coping Strategies Questionnaire. Pain. 1994;57:311–316
  37. Watson D, Clark LA, Tellegen A. Development and validation of brief measures of positive and negative affect: the PANAS scales. J Personality Soc Psychol. 1988;54:1063–1070
  38. Burckhardt CS, Clark SR, Bennett RM. The Fibromyalgia Impact Questionnaire: development and validation. J Rheumatol. 1991;18:728–733
  39. Fallon J, Bujak DI, Guardino S, Weinstein A. The Fibromyalgia Impact Questionnaire: a useful tool in evaluating patients with Post-LD Syndrome. Arthritis Care Res. 1999;12:42–47
  40. Somers RH. A new asymmetric measure of association for ordinal variables. Am Sociol Rev. 1962;27:799–811
  41. R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2007;
  42. Kessler RC, Chiu WT, Demler O, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV Disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62:617–627
  43. Lenzenweger MF, Lane MC, Loranger AW, Kessler RC. DSM-IV personality disorders in the National Comorbidity Survey Replication. Biol Psychiatry. 2007;62:553–564
  44. Thieme K, Turk DC, Flor H. Comorbid depression and anxiety in fibromyalgia syndrome: relationship to somatic and psychosocial variables. Psychosom Med. 2004;66:837–844
  45. Lamberg L. Personality disorder a possibility in “problem” patients, specialists say. JAMA. 2006;296:1341–1342
  46. Giesecke T, Williams DA, Harris RE, et al. Subgrouping of fibromyalgia patients on the basis of pressure-pain thresholds and psychological factors. Arthritis Rheum. 2004;50:2716;author reply 2716-2717
  47. Baker PJ. Perspectives on “Chronic Lyme Disease”. Am J Med. 2008;121:562–564
  48. Moellering RC, Graybill JR, McGowan JE, Corey L. American Society for Microbiology (Antimicrobial resistance prevention initiative—an update: proceedings of an expert panel on resistance). Am J Infect Control. 2007;35:S1–S23
  49. Schiff GD, Wisniewski M, Bult J, et al. Improving inpatient antibiotic prescribing: insights from participation in a national collaborative. Jt Comm J Qual Improv. 2001;27:387–402

 Funding: The National Institute of Mental Health grant number 1 K08MH65360-01.

 Conflict of Interest: Afton L. Hassett, PsyD, Principal Investigator and corresponding author: Dr. Hassett does not have any conflicts of interest associated with this study. For full disclosure, Dr. Hassett has other research funded by Bristol-Myers Squibb (BMS) and is a consultant to BMS and Forest Laboratories; however, this study was not funded by either. There is no foreseeable way for her to gain financially by the results reported herein.

 Diane C. Radvanski, MS, Senior Research Assistant: No conflicts of interest to report. Steven Buyske, PhD, Statistician: Dr. Buyske has no conflicts of interest to report. He does have subcontracts to analyze data related to Dr. Hassett's other research funded by BMS.

 Shantal V. Savage, BA, Research Assistant: No conflicts of interest to report.

 Leonard H. Sigal, MD, Senior Author: Dr. Sigal is the Director of the Pharmaceutical Research Institute at Bristol-Myers Squibb (BMS); however, this study was not funded by BMS, and Dr. Sigal does not stand to gain financially by the results reported herein.

 Authorship: All authors had access to the data and a meaningful role in writing this manuscript.

PII: S0002-9343(09)00342-8

doi: 10.1016/j.amjmed.2009.02.022

The American Journal of Medicine
Volume 122, Issue 9 , Pages 843-850 , September 2009

Article Tools